Tor Skärby

High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia

Tor Skärby, H. Anderson, Jesper Heldrup et al. · Leukemia · 2006 · 122 citations

Hematological Malignancy, Oncology, Pediatric Hematology +8

Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

Sven Nylander, Bengt Kull, Jan‐Arne Björkman et al. · Journal of Thrombosis and Haemostasis · 2012 · 120 citations · Full text

Molecular Pharmacology, Signal Transduction, Blood Platelet +11

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

Michael E. Wechsler, Gene Colice, Janet M. Griffiths et al. · Respiratory Research · 2020 · 86 citations · Full text

High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)

Tor Skärby, Peter Jönsson, Lars Hjorth et al. · Cancer Chemotherapy and Pharmacology · 2003 · 75 citations

Hematological Malignancy, Urology, Acute Lymphoblastic Leukaemia +6

Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study

Gary T. Ferguson, Donald P. Tashkin, Tor Skärby et al. · Respiratory Medicine · 2017 · 72 citations · Full text